The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the most promising pathways for targeted therapies in hepatobiliary and esophagogastric cancers
Tags: ASCO GI Conference CoverageEsophagealLiver (includes HCC, Billiary Tract)
Published: 15 January 2021
Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, discusses the final results of the Phase 3 ClarIDHy trial investigating ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma as presented at the 2021 Gastrointestinal Cancers Symposium
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, considers the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, elaborates on the role of genetic testing in patients with cholangiocarcinoma (CCA)
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, offers opinion on ivosidenib as first-line therapy for patients with cholangiocarcinoma (CCA) and an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the ...
Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, tells us about the results of the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Zev Wainberg, MD, discusses the safety profile of bemarituzumab
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, discusses the safety profile of bemarituzumab from the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, discusses the final results of the Phase 3 ClarIDHy trial investigating ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma as presented at the 2021 Gastrointestinal Cancers Symposium
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, offers opinion on ivosidenib as first-line therapy for patients with cholangiocarcinoma (CCA) and an IDH1 mutation
Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, elaborates on the role of genetic testing in patients with cholangiocarcinoma (CCA)
Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, considers the potential impact of the ClarIDHy trial
Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, considers whether ctDNA testing informs targeted therapy choices for patients with gastric cancer
Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial
Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Zev Wainberg, MD, discusses the safety profile of bemarituzumab
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, discusses the safety profile of bemarituzumab from the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, tells us about the results of the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium
Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer
Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer and whether potential improvements in outcomes are on the horizon for this disease
Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, considers how the progress of targeted therapies in GI cancer compares with progress seen in other tumor types
Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the most promising pathways for targeted therapies in hepatobiliary and esophagogastric cancers
Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, shares perspective on some of the newly approved targeted therapies in hepatobiliary cancer
Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, elaborates on newly approved targeted therapies in esophagogastric cancer
Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, tells us about the NuTide:121 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium are practice changing
Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding how we treat patients with HR+, HER2- breast cancer that has spread to 1-3 lymph nodes
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.